New pharmacological approach could treat type 2 diabetes
Source: Rainer Rillke CC-By-SA GFDL release
Insulin resistance is a hallmark of type 2 diabetes yet current anti-diabetic drugs do not correct this defect. One driver of insulin resistance is ectopic lipid accumulation in the liver and muscle, which is the target of a new therapeutic approach described in Nature Medicine (online, 5 October 2014).
Shengkan Jin, from Rutgers University, New Jersey, and colleagues evaluated a derivative of the anthelmintic drug niclosamide, which acts through mitochondrial uncoupling. Niclosamide ethanolamine salt (NEN) prevented and treated hepatic steatosis, improved glycaemic control and delayed disease progression in genetic and dietary mouse models of diabetes.
“Given the well-documented safety profile of NEN, our study provides a potentially new and practical pharmacological approach for treating type 2 diabetes,” says the team.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066755
Recommended from Pharmaceutical Press
This new edition of Dale and Appelbe's Pharmacy and Medicines Law is the definitive guide to law and ethics for pharmacy practice in the UK. It covers law and professional regulation and is firmly established as the definitive student textbook and reference work on this subject in the UK. Fully updated to include changes to pharmacy laws and regulation.£57.00Buy now
Pharmacy Registration Assessment Questions features over 400 closed book and calculation questions. With the registration exam having gone through a complete transformation in 2016, this volume has been developed around the new General Pharmaceutical Council (GPhC) guidelines.